Celcuity Inc. (CELC)

NASDAQ: CELC · IEX Real-Time Price · USD
8.96
-0.13 (-1.43%)
Jul 5, 2022 4:30 PM EDT - Market closed

Company Description

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States.

The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer.

The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells.

It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Celcuity Inc.
Country United States
Founded 2011
IPO Date Sep 20, 2017
Industry Biotechnology
Sector Health Care
Employees 39

Contact Details

Address:
16305–36th Avenue North
Minneapolis, MN 55446
United States
Phone 763 392 0767
Website celcuity.com

Stock Details

Ticker Symbol CELC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001603454
CUSIP Number 15102K100
ISIN Number US15102K1007
Employer ID 82-2863566
SIC Code 8071

Key Executives

Name Position
Brian F. Sullivan Co-Founder, Chairman and Chief Executive Officer
Dr. Lance G. Laing Ph.D. Co-Founder, Chief Science Officer, Vice President, Secretary and Director
Vicky Hahne Chief Financial Officer
Eric Lindquist Chief Business Officer
Dr. Arthur P. DeCillis M.D. Chief Medical Officer
Dr. John R. MacDonald Dabt, Ph., Ph.D. Senior Vice President of Research & Development
Sheri Smith Acting Head of Clinical Operations
Igor Gorbatchevsky M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
May 31, 2022 S-8 Securities to be offered to employees in employee benefit plans
May 26, 2022 D Notice of Exempt Offering of Securities
May 26, 2022 4 Statement of changes in beneficial ownership of securities
May 25, 2022 SC 13G Statement of acquisition of beneficial ownership by individuals
May 25, 2022 SC 13G Statement of acquisition of beneficial ownership by individuals
May 25, 2022 4 Statement of changes in beneficial ownership of securities
May 24, 2022 SC 13D General statement of acquisition of beneficial ownership
May 23, 2022 4 Statement of changes in beneficial ownership of securities
May 19, 2022 4 Statement of changes in beneficial ownership of securities
May 19, 2022 4 Statement of changes in beneficial ownership of securities